Company: DVAX
Filing Date: 2025-04-17
Form Type: DEFC14A
Source: 0000930413-25-001273
Chunk: 51

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: DEFC14A
Chunk 51
---
 compensation in 2024 for services provided as            
 a member of our Board.                                                                                                         |
| (2) | Consists of fees earned or paid in 2024 for Board and committee membership as described above.                                 |
| (3) | Represents the aggregate grant date fair value of stock options and RSUs, as applicable, granted                               
 in the fiscal year in     accordance with ASC 718. See Note 15 - Equity Plans and Stock-Based Compensation, in the Notes       
 to Consolidated Financial     Statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on           
 February 20, 2025, for a discussion     of assumptions we made in determining the compensation costs included in this column.  
 These amounts do not necessarily correspond     to the actual value recognized or that may be recognized by the non-employee   
 directors.                                                                                                                     |
| (4) | As of December 31, 2024, each then-serving non-employee director held outstanding stock options and RSUs to purchase the       
 following numbers of shares of our common stock: Mr. Myers held options to purchase 106,875 shares of our common stock and     
 RSUs covering 25,446 shares of our common stock; Dr. Cano held options to purchase 148,800 shares of our common stock          
 and RSUs covering 16,071 shares of our common stock; Ms. Eastland held options to purchase 142,500 shares of our common stock  
 and RSUs covering 16,071 shares of our common stock; Dr. Kisner held options to purchase 168,200 shares of our common stock    
 and RSUs covering 16,071 shares of our common stock; Mr. MacGregor held options to purchase 142,500 shares of our common stock 
 and RSUs covering 16,071 shares of our common stock; Dr. Paradiso held options to purchase 136,250 shares of our common stock  
 and RSUs covering 16,071 shares of our common stock; Ms. Phillips held options to purchase 168,200 shares of our common stock  
 and RSUs covering 16,071 shares of our common stock; and Ms. Sun held options to purchase 101,250 shares of our common stock   
 and RSUs covering 24,107 shares of our common stock.                                                                           |
| (5) | Dr. Paradiso was a consultant during 2024, and his compensation includes an additional $14,750 for consulting fees.            |

| 36